| Literature DB >> 6124803 |
D W Costain, P J Cowen, M G Gelder, D G Grahame-Smith.
Abstract
The growth-hormone (GH) response to subcutaneous administration of the dopamine agonist, apomorphine (0.005 mg/kg), was assessed in 15 depressed patients at the beginning and at the end of a course of electroconvulsive therapy (ECT). After ECT there was a significant increase in the GH response to apomorphine, supporting the hypothesis that ECT produces an enhancement of dopamine-mediated responses in the brain. Additional studies in depressed patients receiving other antidepressant treatment suggested that the increase in apomorphine response following ECT was not attributable either to concurrent antidepressant medication or to clinical recovery from depressive illness.Entities:
Mesh:
Substances:
Year: 1982 PMID: 6124803 DOI: 10.1016/s0140-6736(82)90438-x
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321